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Mesothelioma affects approximately 3000 people each year in the United States. For unresectable malignant 
pleural mesothelioma patients, the 5-year survival rates 
remain dismal. Currently, platinum-pemetrexed is the stan-
dard regimen recommended for frontline therapy. Numerous 
targeted agents have been tried in small studies but none have 
reached the threshold for Food and Drug Administration 
approval in the salvage or frontline setting. Several ongoing 
and recently completed studies were discussed in the meso-
thelioma session.
SUMMARY OF PRESENTATIONS
There were three presentations for the mesothelioma 
session. Dr. Donington gave a concise overview of the active 
trials and recently completed studies. Some of the high-
lights from this presentation demonstrated that certain anti-
angiogenic agents have clinical benefit in a subpopulation of 
mesothelioma patients. From the phase II salvage sunitinib 
monotherapy trial there were four of 22 patients showed par-
tial response (PR). In a separate randomized, phase II, front-
line trial patients who had lower median vascular endothelial 
growth factor serum levels had an overall survival (OS) benefit 
when treated with bevacizumab-platinum-gemcitabine com-
pared with platinum-gemcitabine alone. Southwest Oncology 
Group (SWOG) 0905, a phase I/II trial, has completed the 
phase I portion, which treated all patients with cisplatin-
pemetrexed-cediranib and is actively accruing patients to the 
randomized phase II section (cisplatin-pemetrexed + cedira-
nib). A phase III trial of asparagine-glycine-arginine (NGR)-
human tumor necrosis factor (hTNF) + chemotherapy versus 
chemotherapy is also ongoing; NGR-hTNF is a tumor specific 
peptide NGR bound to TNF. The phase II trial of NGR-hTNF 
had one PR of 57 patients, a median progression-free survival 
(PFS) of 2.8 months and median OS 12.1 months in pretreated 
mesothelioma patients.
In addition to the antiangiogenic agents, the results 
of the international phase III Vorinostat Clinical Trials in 
Hematological and Solid Malignancies (VANTAGE) 014 sal-
vage trial (vorinostat versus placebo in patients who failed 
prior pemetrexed and platinum therapy) were discussed. As 
presented in Stockholm, September 2011, there was no differ-
ence in response rate or dyspnea score, and the median PFS 
was 6.3 weeks for vorinostat compared with 6.1 weeks for 
placebo. Treatment with vorinostat provided a median OS of 
31 weeks compared with placebo at 27 weeks. Unfortunately, 
further development of vorinostat in mesothelioma is halted 
pending biomarker and further analysis. Additional salvage 
trials mentioned included the phase I focal adhesion kinase 
(FAK) inhibitor GSK22560989 and SWOG 0722, a phase II 
trial of everolimus in salvage mesothelioma patients. In the 
neoadjuvant setting, the Department of Defense-sponsored 
neoadjuvant dasatinib (Src kinase, platelet derived growth 
factor receptor inhibitor) trial was mentioned as it is cur-
rently completing accrual at M.D. Anderson Cancer Center. 
This trial is biomarker-based and will provide a more detailed 
assessment of mesothelioma tumor heterogeneity and Src 
kinase modulation pre- and postdasatinib therapy.
Dr. Ibrahim moved the discussion into immunotherapy 
for mesothelioma. Tremelimumab is a monoclonal antibody 
that targets cytotoxic T-Lymphocyte Antigen 4. It is fully 
human and is presumed to potentiate antitumor activity. A 
phase II trial in second-line chemotherapy-resistant mesothe-
lioma patients (N = 29) using tremelimumab (15 mg/kg) was 
performed with 22 evaluable patients. There were two PRs and 
four patients with prolonged stabilization of disease. The pre-
liminary median OS (n = 11) reported was 17.5 months. One 
patient had an initial progression of disease after two cycles of 
therapy and then a substantial PR after the fourth cycle. The 
main toxicities reported were mild—only two patients experi-
enced any grade 3 or 4 toxicity. The grade 3–4 adverse events 
included gastrointestinal toxicity, hepatitis, and pancreatitis. 
The most common side effect was grade 1–2 skin rash (82%), 
and colitis/diarrhea (41%), and fever (32%). It is presumed 
that the colitis and hepatitis are autoimmune related. This 
phase II trial demonstrates similar responses to prior immuno-
modulator trials in other tumor types. Further investigation of 
this agent in mesothelioma is underway.
The last presentation by Dr. Tsao focused on a bio-
marker overview in mesothelioma highlighting germline/
somatic mutations, serum markers, prognostic tumor mark-
ers for surgery, and predictive biomarkers to chemotherapy 
and targeted agents. The mutation section reviewed the 
germline mutations found in Cappadocia Turkey (autosomal 
dominant inheritance with erionite exposure) and the newest 
BAP1 (BRCA1 associated protein-1) mutation, which can 
predispose patients to familial and sporadic mesothelioma 
and uveal melanoma. It is suspected that asbestos exposure 
predisposes BAP1 patients to developing mesothelioma 
before uveal melanoma. BAP1 can also occur as a somatic 
mutation as it is a tumor-suppressor gene located on chro-
mosome 3p21. Other somatic mutations found in mesotheli-
oma tumor specimens included deletion of CDKN2 (located 
on 9p21) and loss of NF2 (located on 22q12). Preclinical 
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studies show that loss of NF2 protein merlin correlates with 
an increase in FAK, which mediates growth-factor signal-
ing and adhesion-dependent signaling needed for tumor cell 
proliferation. GSK2256098, an FAK inhibitor, is currently 
being evaluated in a phase I trial of solid tumors; in addition, 
a specific investigation focused on mesothelioma patients 
and biomarker FAK expression/NF2 loss is underway.
Screening serum markers were briefly mentioned: 
osteopontin, soluble mesothelin-related peptide (SMRP), and 
megakaryocyte potentiating factor (MPF). Osteopontin is a 
glycoprotein that mediates cell-matrix interactions and higher 
serum levels of osteopontin are seen in asbestos workers who 
develop mesothelioma. SMRP is a glycoprotein located on the 
cell surface of normal mesothelial cells, ovarian and mesothe-
lioma tumor cells. MPF is a soluble protein encoded by the 
MSLN gene. Proteolytic cleavage of MSLN precursor protein 
leads to MPF (N-terminal) and mesothelin. Although osteo-
pontin and MPF are elevated in mesothelioma patients, these 
assays are not able to predict outcomes nor correlate with the 
amount of disease. Resurgence of SMRP levels in mesotheli-
oma patients may be able to identify recurrence in resected or 
debulked patients who have an initial drop in SMRP postop-
eratively. Combining these three serum markers in a panel has 
not provided better predictive ability compared with SMRP 
alone.
Two separate prognostic tumor biomarker reports for 
surgery were reviewed. This section is of significance as the 
recent Mesothelioma and Radical Surgery (MARS) trial1 
reported that mesothelioma patients did not have benefit 
from extrapleural pneumonectomy, and raised the question 
of whether aggressive surgical resection should ever be per-
formed in mesothelioma patients. Identification of a prognos-
tic biomarker would be able to optimize the decision to proceed 
with aggressive surgery. From the Boston group,2 a 4-gene 
expression ratio test was reported to have 88.5% repeatability 
and 96.1% reproducibility to determine a good risk versus a 
poor risk patient for surgical resection. Three ratios of gene 
expression were used (TM4SF1/PKM2, TM4SF1/ARHFDIA, 
COBLL1/ARHGDIA). The limitations of this method are that 
it is difficult to produce real-time and also does not account for 
tumor heterogeneity. Gene-expression arrays are also highly 
variable. The second prognostic biomarker report originates 
from M.D. Anderson Cancer Center. A retrospective analysis 
of archived tumor specimens identified that PDGFR. Further 
prospective analysis of this biomarker is needed for validation.
Last, the predictive biomarker section had conflicting 
data from the literature for several markers. The tumor excision 
repair cross-complementation group 1 baseline immunohisto-
chemistry scores were not predictive of platinum resistance 
in two phase II trials.3,4 One study3 (N = 45) reported that 
higher tumor excision repair cross-complementation group 1 
was prognostic of an improved OS; however, the larger trial4  
(N = 99) did not show an OS difference. Baseline lower 
immunohistochemistry scores of thymidylate synthase were 
predictive of an improved PFS and OS in both trials. In a phase 
II randomized trial of cisplatin-gemcitabine + bevacizumab, 
lower median baseline serum vascular endothelial growth fac-
tor levels seemed to be prognostic and predictive for both a 
PFS and OS benefit. This serum-biomarker analysis suggests 
that a population of mesothelioma patients is highly reliant on 
the angiogenic pathway and would benefit from antiangiogenic 
therapy. In the resectable population, two targeted-therapy tri-
als with biomarker assessment in pleural mesothelioma are 
underway. The neoadjuvant dasatinib trial conducted at M.D. 
Anderson has presented preliminary data that inhibiting Src 
kinase Tyr419 with dasatinib is predictive of improved RR and 
PFS in a subgroup of mesothelioma patients. At Memorial 
Sloan Kettering, and soon M.D. Anderson, a Department of 
Defense-sponsored adjuvant trial using WT-1 vaccine is open 
for enrollment. WT-1, a transcription factor, is commonly 
expressed on mesothelioma tumor cells and is typically pro-
cessed and presented to the immune system. This peptide 
vaccine induced T-cell recognition to attack WT-1 expressing 
mesothelioma tumor cells.
FUTURE DIRECTIONS
It is evident from the growing body of literature and 
studies that mesothelioma patients can benefit from individu-
alized therapy and identification of predictive and prognos-
tic biomarkers. Gene mutations identify distinct populations 
of patients and may ultimately guide therapeutic decisions 
as these driver-mutation tumors may have a different natural 
biology. Screening serum markers for mesothelioma remain 
under development, but SMRP can be used postoperatively 
to identify recurrent disease. Prospective real-time validation 
of prognostic molecular biomarkers is critically needed to 
identify mesothelioma patients who will benefit from aggres-
sive surgical resection. Trials in unresectable mesothelioma 
patients need to be designed with translation correlates that 
identify predictive biomarkers for novel agents and commonly 
used chemotherapies. Future development of immunotherapy-
based regimens may further advance the field.
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